Ophthalmology
-
Randomized Controlled Trial Multicenter Study
Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE.
To evaluate the efficacy and safety of intravitreal ranibizumab in diabetic macular edema (DME) patients. ⋯ Ranibizumab rapidly and sustainably improved vision, reduced the risk of further vision loss, and improved macular edema in patients with DME, with low rates of ocular and nonocular harm.